AMR€72M from Novo´s REPAIR Impact Fund for Group B Streptococcus vaccinesMinervaX inks €72m financing deal with Novo Holdings REPAIR Impact Fund to develop a vaccine against Group B Streptococcus. more ➔
A ray of hope in leukaemiaA child with recurrent T-cell leukaemia was given base-edited T-cells in a world-first application of a base-edited cell therapy. more ➔
Amgen wins race of top `22 deals with $26bn for Horizon thxAccording to Bloomberg, the US biotechnology giant Amgen plans to buy Horizon Therapeutics at a valuation of about $26bn. Overall, the deal corresponds to an enterprise value including debt of $28.3bn. … more ➔
Step Pharma presents promising cancer treatmentStep Pharma intruduces promising data on the potential of a selective cancer treatment by inhibition of CTPS1 with their inhibitor STP938. more ➔
Partnering revitalized at the BioFit2022 – in Strasbourg and onlineThe partnering event BioFit2022 took place in Strasbourg, France on November 29th and 30th as well as online on December 7th and 8th. It reflected on challenging times in the pandemic, survivors’ of … more ➔
M&AEuropean Commission calls for reversal of Illumina’s $7bn Grail merger The European Commission has now recommended concrete steps that, while not yet final, would require Illumina to "swiftly" reverse its controversial $7.1bn acquisition of Grail. more ➔
partnershipBioNTech and Ryvu Therapeutics enter into global collaborationRenewed focus on cancer: COVID-19 vaccine company BioNTech SE (Nasdaq: BNTX) and Ryvu Therapeutics S.A., located in Krakow (Warsaw Stock Exchange: RVU), a Polish clinical-stage cancer therapeutics development … more ➔
M&AAmsterdam Neogene Therapeutics aquired by AstraZeneca AstraZeneca announced an agreement to acquire Neogene Therapeutics Inc. (Neogene), a global clinical-stage biotechnology company spezialised in next-generation T-cell receptor therapies (TCR-Ts) that … more ➔
ObesityNovo Nordisk funds API manufacturing with €726mNovo Nordisk A/S invests €726m to expand facilities and to produce APIs to supply the company’s global clinical trials. more ➔
partnershipSOTIO licences first cancer ADC from LegoChem BiosciencesSOTIO Biotech a.s. has exercised its first of five exclusive, target-specific options for antibody-drug conjugate (ADC) SOT106 under its agreement with LegoChem Biosciences Inc. more ➔
